Welcome to our dedicated page for MedTech Acquisition Corporation news (Ticker: MTAC), a resource for investors and traders seeking the latest updates and insights on MedTech Acquisition Corporation stock.
MedTech Acquisition Corporation (MTAC), a specialized SPAC targeting transformative medical technology companies, provides investors and industry observers with critical updates through this centralized news hub. Track merger developments, partnership announcements, and strategic moves within the dynamic healthcare innovation sector.
This resource delivers timely updates on MTAC's progress in identifying acquisition targets across medical devices, diagnostics, and digital health. Users gain insights into the company's evaluation criteria for potential mergers and its role in bringing emerging technologies to public markets.
The page aggregates official announcements regarding financial positioning, leadership insights, and sector-specific developments. Recent coverage includes MTAC's engagement with therapeutic innovators like TriSalus Life Sciences, reflecting its focus on clinically impactful technologies.
Bookmark this page for streamlined access to MTAC's evolving story as it shapes the future of medical technology through strategic acquisitions. Check back regularly for verified updates directly impacting the healthcare investment landscape.
TriSalus Life Sciences has announced new Phase 1 clinical data at the AACR 2023 Annual Meeting regarding its Pressure-Enabled Regional Immuno-Oncology (PERIO-01) trial for uveal melanoma with liver metastases. The trial, utilizing the investigational drug SD-101 delivered via the TriNav Infusion System, aims to enhance systemic checkpoint inhibitors' effectiveness. Of 27 enrolled patients, treatment-related adverse events were mostly non-serious, with one significant event reported. Encouragingly, ctDNA and circulating tumor cell levels decreased in several patients, indicating potential improved survival outcomes. TriSalus is preparing for a business combination with MedTech Acquisition Corporation (MTAC), projected to list under the ticker TLSI, pending necessary approvals.
TriSalus Life Sciences announced the appointment of Jim Alecxih as President of Device Technology Business. With over 30 years of experience in product development and commercialization, Alecxih will oversee the growth of the TriNav Infusion System, which has been used in over 17,000 procedures. The Company is in the process of going public through a merger with MedTech Acquisition Corporation (ticker: MTAC) expected to close in Q2 2023, pending shareholder approval. TriSalus aims to disrupt cancer treatment for liver and pancreatic tumors through innovative drug delivery technology.
TriSalus Life Sciences, an oncology firm, has released new data on its Pressure-Enabled Regional Immuno-Oncology (PERIO) studies for treating liver tumors. The ongoing PERIO-01 and PERIO-02 trials assess SD-101's intravascular delivery using the TriNav Infusion System. Results show a decrease in circulating tumor DNA for uveal melanoma patients treated with SD-101 and nivolumab, indicating potential survival benefits. With 42 patients enrolled as of February 2023, TriSalus anticipates additional data by Q2 2023 and is expanding its clinical sites ahead of Phase 2 programs set for later this year.
TriSalus Life Sciences is advancing its Pressure-Enabled Regional Immuno-Oncology clinical program through a business combination with MedTech Acquisition Corporation (MTAC). The company has opened five additional PERIO-01 clinical trial sites across major U.S. institutions, including Stanford and UCLA, for its investigational drug SD-101. The trials aim to improve immunotherapy efficacy in patients with liver metastases from uveal melanoma and those with hepatocellular carcinoma. Promising pre-clinical data supports the potential of SD-101 to enhance therapy outcomes.
MedTech Acquisition Corporation (NASDAQ: MTAC) has postponed its special meeting of stockholders to December 12, 2022, to secure more votes for the Extension Amendment. This amendment seeks to extend the deadline for completing a business combination from December 22, 2022, to June 22, 2023. The company is currently working to finalize a merger with TriSalus Life Sciences, Inc.. Stockholders as of the record date, October 24, 2022, can still vote regardless of share sales.
Approval of the merger is critical for the company’s future as it plans to rebrand as TriSalus Life Sciences upon completion.
TriSalus Life Sciences has announced a definitive merger agreement with MedTech Acquisition Corporation (NASDAQ: MTAC). This merger aims to transform cancer treatment through innovative drug delivery technologies, specifically targeting liver and pancreatic tumors. Post-transaction, TriSalus expects a market capitalization of approximately $244.4 million. The merger will facilitate the commercialization of its FDA-cleared TriNav® Infusion System and advance its investigational therapy, SD-101. The deal is projected to close in Q1 2023, bringing TriSalus more than $60 million in cash, including $50 million from a convertible note.
MedTech Acquisition Corporation (Nasdaq: MTAC) and Memic Innovative Surgery Ltd. have mutually agreed to terminate their business combination agreement due to market volatility. This decision, effective immediately, reflects the challenges posed by recent global events. Despite the termination, both companies express optimism, with Memic highlighting the successful adoption of its Hominis system by leading U.S. hospitals, aimed at advancing surgical practices in women's health and general surgery.
FAQ
What is the market cap of MedTech Acquisition Corporation (MTAC)?
